Navigation Links
Empire BlueCross BlueShield Appoints Chief Medical Officer
Date:12/9/2008

NEW YORK, Dec. 9 /PRNewswire/ -- Empire BlueCross BlueShield announced today the appointment of Scott Breidbart, M.D. as its Chief Medical Officer. Dr. Breidbart will play a key role as liaison between Empire BlueCross BlueShield, the company's more than 5 million members, their physicians and other health care providers across the state.

"As the nation and health care industry embrace a culture of responsible health maintenance and high-quality, affordable treatment, it is critical to create collaborative relationships between consumers, their doctors and insurers," said Mark Wagar, president and CEO, Empire BlueCross BlueShield. "We are extremely pleased to have someone of Dr. Breidbart's credentials, experience and reputation join our staff and anticipate that our provider partners and members will benefit from his knowledge immediately."

Dr. Breidbart assumes the role previously held by Dr. John Whitney, who has accepted another position within the company. Dr. Breidbart joins Empire BlueCross BlueShield with more than 15 years of managed care experience and more than 10 years as a medical practitioner in New York. Most recently he served as vice president, Quality Improvement and Medical Policy at Health Net, where he built and managed clinical account management teams on both coasts and built and directed the medical profiling team.

Dr. Breidbart received his undergraduate degree from Yale University and earned his medical degree from Columbia University. He performed his residency in pediatrics at Babies Hospital (Columbia Presbyterian), his chief residency at Westchester Medical Center and his fellowship in Pediatric Endocrinology at Montefiore Medical Center.

Additionally, he practiced pediatric endocrinology for 10 years as Assistant Professor of Pediatrics, New York Medical College.

Dr. Breidbart also holds an MBA from Pac
'/>"/>

SOURCE Empire BlueCross BlueShield
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Empire BlueCross BlueShield Associates Commit Over $1 Million to Community Organizations in 2008
2. Empire Blue Cross Blue Shield Announces Initiative to Protect Members Health Aimed at Preventing Serious Medical Errors
3. Empire Blue Cross Blue Shield Statement in Response to New York Attorney Generals Recent Subpoenas
4. Loma Linda University Medical Center Celebrates Groundbreaking on Inland Empires Most Comprehensive Rehabilitation Center
5. Empire BlueCross BlueShield and New York Attorney General Reach Agreement on Guidelines for State Doctor Ranking Programs
6. Empire BlueCross BlueShield Announces Release of State Health Index Data
7. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
8. Assured Pharmacy Retains Empire Financial Group
9. Capital BlueCross Receives Prestigious Corporation of the Year Award
10. Capital BlueCross Sponsors Healthy Community Pharmacys Move to New Community-Focused Location in York
11. Capital BlueCross Adds Dental Plan to Product Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 1Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 2Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 1Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 2Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 1Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 2Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 3Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 5Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 6Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 7Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 8Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 9